Applied DNA Sciences, Inc.: Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA COVID-19 Vaccine Candidate for Feline Veterinary Market
(2) - Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models - Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ("Evvivax"), today announced the initiation of Phase I of a two-phase clinical trial to evaluate a LinearDNA COVID-19 vaccine candidate for ...
Source: finanznachrichten.de